For broader research context on nootropic compounds, including comparative stacks, cycling considerations, and interaction notes, see the Complete Nootropic Cheat Sheet.
What Is NAD+?
Nicotinamide Adenine Dinucleotide (NAD+) is an essential coenzyme present in every living cell and fundamental to hundreds of metabolic reactions. It serves dual roles: as an electron carrier in cellular respiration and as a substrate consumed by enzymes including sirtuins (longevity-associated deacylases), PARPs (DNA repair enzymes), and CD38 (a NAD+ hydrolase). The tension between these roles is central to aging biology.
NAD+ Decline with Aging
Cellular NAD+ levels decline by 40–60% between young adulthood and old age, driven by increased CD38 activity, accumulated DNA damage activating PARP enzymes, and reduced biosynthesis capacity. This decline impairs sirtuin activity, reduces mitochondrial biogenesis, compromises DNA repair fidelity, and accelerates the metabolic deterioration associated with aging.
Sirtuin Activation and Research
Sirtuins (SIRT1–7) are NAD+-dependent protein deacylases that regulate metabolism, stress resistance, genome stability, and aging at the epigenetic level. Restoring NAD+ levels through precursors (NMN, NR) or through NNMT inhibition reactivates these protective pathways. NAD+ repletion is studied for aging, cognitive decline, metabolic syndrome, hearing loss, kidney disease, and addiction recovery — reflecting NAD+'s ubiquitous role in cellular health.
Quick Reference
Member reference tables summarize the compound's research parameters.
Research Indications
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.
This member section describes parameters reported in the research literature.
Peptide Interactions
This member section summarizes reported compound interactions and evidence limitations.
Reported Research Time Points
This member section summarizes reported research time points.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
This member section discusses research safety considerations and uncertainties.
Quality Indicators
Research Citations
- Intranasal NAD+ for Traumatic Brain Injury (2012)
Rats | 20 mg/kg intranasal | Post-TBI treatment | Hippocampal neuroprotection - Nicotinamide Riboside Safety & Metabolism Study (2019)
Human | 100-1000mg oral daily | 8 weeks | Well-tolerated, increased NAD+ - Age-Associated NAD+ Decline in Human Tissue (2012)
Human tissue analysis | Multiple organs studied | Cross-sectional | 10-50% decline with age - Nicotinamide Riboside Bioavailability in Humans (2016)
Human | 100-1000mg oral | Single dose pharmacokinetics | Dose-dependent NAD+ elevation - NMN Efficacy in Middle-Aged Adults (2022)
Human | 300-900mg oral daily | 60 days | Multicenter RCT - CD38-Targeting Peptide Vaccine Ameliorates Aging-Associated Phenotypes in Mice
Yu S, Li Z, Tang Y, 2025, Aging Cell - From Pharmacophore to Warhead: NAD(+)-Targeting Triazoles as Mechanism-Based Sirtuin Inhibitors
Friedrich F, Meleshin M, Papenkordt N, 2025, Angew Chem Int Ed Engl - Mono-ADP-Ribosylation Catalyzed by Arginine-Specific ADP-Ribosyltransferases
Stevens LA, Moss J, 2018, Methods Mol Biol - NAD-dependent ADP-ribosylation of the human antimicrobial and immune-modulatory peptide LL-37 by ADP-ribosyltransferase-1
Picchianti M, Russo C, Castagnini M, 2015, Innate Immun - NAD attenuates oxidative DNA damages induced by amyloid beta-peptide in primary rat cortical neurons
Wu MF, Yin JH, Hwang CS, 2014, Free Radic Res